Navigation Links
Affymetrix Standard Data Analysis Report from Asuragen, Inc.

ProductsAffymetrix Standard Data Analysis Report from Asuragen, Inc.
Company Asuragen, Inc.
Item Affymetrix Standard Data Analysis Report
Price 
Description Maximize the value of your microarray data using Asuragens bioinformatics expertise. We offer the support you need from consultation to extensive data analysis using the most up to date methods. Utilize our expertise in combination with the Gene Expression Profiling Service or from your own microarray experiments.
Raw data report from Affymetrix GeneChip
Info Asuragen, Inc.
2150 Woodward
Suite 100
Austin, TX 78744-1832
Customer Service: +1 512 651-0191
Fax Number: +1 512 651-0601
Web Site: http://www.asuragen.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Affymetrix SSP Data Analysis Report from Asuragen, Inc.
2. Standard Protein Kinase Substrate (PKS) Peptide Microarray from LC Sciences
3. Standard DNA Aptamer Microarray from LC Sciences
4. Standard 2-F RNA Aptamer Microarray from LC Sciences
5. Standard 2-OMe RNA Aptamer Microarray from LC Sciences
6. Illumina Standard Data Analysis Report from Asuragen, Inc.
7. Organic Acid Analysis Standard, 6 vials from Bio-Rad
8. Carbohydrate Analysis Standard, 6 vials from Bio-Rad
9. ICS-1500 Standard Integrated IC System from Dionex Corporation
10. GeneChoice Taq DNA Polymerase With Standard Buffer from GeneChoice, Inc.
11. GeneChoice Taq DNA Polymerase With Magnesium Free Standard Buffer from GeneChoice, Inc.
The Freeze 'N Squeeze DNA gel extraction kit uses a quick freeze-and-thaw cycle and centrifugation to draw 50-23,000 bp DNA out of agarose gel slices. The kit includes materials for 100 preps....
... Ciphergen's ProteinChip arrays have been ... from biological samples. A variety of ... of proteins according to their unique ... different spots, allowing side-by-side sample comparison, ...
This thermal printer, 120 V, provides a permanent record of the preprogrammed method and run data for the PROTEAN IEF cell. Includes cable and power adaptor....
... Leu DAP FLISP Assay with FAM-Labeled ... nm) • Accurately measure serine protease ... permeabilization • B-Bridge's FLISP Kits utilize ... proteases (FLISPs) to measure chymotrypsin-like activity ...
Biology Products:
(Date:12/8/2013)... addition of a monoclonal antibody called gemtuzumab combined ... reduce the risk of relapse and increase rates ... myeloid leukemia (AML). Post-treatment relapse rates are a ... children with the disease. , The study (abstract ... 10 years old at trial sites nationwide, led ...
(Date:12/7/2013)... December 7, 2013) Hematopoietic stem cell transplantation ... to drug therapy for blood cancer, has become ... of patients as a result of major advances ... these advances were presented today during the 55th ... in New Orleans. , HSCT is effectively used ...
(Date:12/6/2013)... Dec. 6, 2013 /PRNewswire-iReach/ -- Last month, a team ... visited Texas Children,s Heart Center to observe best practices ... doctors and nurses, was led by Rotarian physician Dr. ... with Baylor College of Medicine (BCM), The Rotary Foundation, ... Club of West U. (Photo: http://photos.prnewswire.com/prnh/20131206/MN29207 ...
Breaking Biology News(10 mins):Targeted treatment can significantly reduce relapse in children with AML leukemia 2International gene therapy trial for 'bubble boy' disease shows promising early results 2International gene therapy trial for 'bubble boy' disease shows promising early results 3International gene therapy trial for 'bubble boy' disease shows promising early results 4International gene therapy trial for 'bubble boy' disease shows promising early results 5International gene therapy trial for 'bubble boy' disease shows promising early results 6International gene therapy trial for 'bubble boy' disease shows promising early results 7Uganda Heart Institute physicians and nurses visit Texas Children's Heart Center 2Uganda Heart Institute physicians and nurses visit Texas Children's Heart Center 3
... University of Cincinnati researchers may sniff out olfactory disorders ... Parkinson’s disease and other problems outside the typical sensory ... an invention of UC Psychology Professor Robert Frank and ... Cell Biology, is now under further development with the ...
... have long said they won't be able to understand the ... map of how billions of neurons are interconnected. Now, researchers ... many believe to be a major hurdle to preparing that ... , In the March 1 issue of the journal Neuron, ...
... The National Institute of Allergy and Infectious Diseases (NIAID), ... announced it is awarding $23 million per year for ... Influenza Research and Surveillance. Collectively, the centers will expand ... States, and will bolster influenza research in key areas, ...
Cached Biology News:Get a whiff of this: Smell test could sniff out serious health problems 2Get a whiff of this: Smell test could sniff out serious health problems 3Deconstructing brain wiring, one neuron at a time 2Deconstructing brain wiring, one neuron at a time 3NIAID expands capability for influenza research and surveillance 2NIAID expands capability for influenza research and surveillance 3NIAID expands capability for influenza research and surveillance 4
(Date:12/9/2013)... RICHMOND, Calif. , Dec. 9, 2013 /PRNewswire/ ... ) announced the presentation of preclinical data from ... potential cure of both sickle cell disease (SCD) ... using its proprietary and highly specific zinc finger ... the expression of fetal gamma-globin in adult red ...
(Date:12/9/2013)... 2013 MiMedx Group, Inc.  (NASDAQ: MDXG), ... protected regenerative biomaterials and bioimplants processed from human ... subject to market and other conditions, 5,000,000 shares ... offering. The Company expects to grant the underwriters ... additional 750,000 shares of common stock to cover ...
(Date:12/9/2013)... Dec. 9, 2013 Intra-Cellular Therapies, ... biopharmaceutical company focused on the development of ... announced today positive topline results from the ... clinical trial of its lead drug candidate, ... In this study, ITI-007 met the trial,s ...
(Date:12/9/2013)... Dec. 9, 2013 Spherix Incorporated (NASDAQ: ... the fostering and monetization of intellectual property, ... IP LLC filed suit on December 6, ... LLC (collectively "Defendants") for infringement of Patent ... Determining the Geolocation of a Transmitter." Guidance IP ...
Breaking Biology Technology:Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting 2Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting 3Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting 4Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting 5Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting 6Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting 7MiMedx Group Announces Proposed Public Offering of Common Stock 2MiMedx Group Announces Proposed Public Offering of Common Stock 3Intra-Cellular Therapies Announces Positive Topline Phase II Clinical Results of ITI-007 for the Treatment of Schizophrenia 2Intra-Cellular Therapies Announces Positive Topline Phase II Clinical Results of ITI-007 for the Treatment of Schizophrenia 3Intra-Cellular Therapies Announces Positive Topline Phase II Clinical Results of ITI-007 for the Treatment of Schizophrenia 4Intra-Cellular Therapies Announces Positive Topline Phase II Clinical Results of ITI-007 for the Treatment of Schizophrenia 5Intra-Cellular Therapies Announces Positive Topline Phase II Clinical Results of ITI-007 for the Treatment of Schizophrenia 6Intra-Cellular Therapies Announces Positive Topline Phase II Clinical Results of ITI-007 for the Treatment of Schizophrenia 7Intra-Cellular Therapies Announces Positive Topline Phase II Clinical Results of ITI-007 for the Treatment of Schizophrenia 8Intra-Cellular Therapies Announces Positive Topline Phase II Clinical Results of ITI-007 for the Treatment of Schizophrenia 9Intra-Cellular Therapies Announces Positive Topline Phase II Clinical Results of ITI-007 for the Treatment of Schizophrenia 10Spherix's Wholly Owned Subsidiary Sues AT&T Inc. and AT&T Mobility for Infringement of Patent for Geolocation of Cell Phones in Second Cell Phone Location Suit for Spherix 2Spherix's Wholly Owned Subsidiary Sues AT&T Inc. and AT&T Mobility for Infringement of Patent for Geolocation of Cell Phones in Second Cell Phone Location Suit for Spherix 3